Atrium Health Levine Cancer | Strategic Alliance Partners

May 04, 2020

R. Wendel Naumann, MD, discusses the FDA approval of niraparib in ovarian cancer and the impact on the current treatment paradigm.

May 02, 2020

Peter Voorhees, MD, discusses the evolution of idecabtagene vicleucel (ide-cel; bb2121) in the phase 2 KarMMa study in relapsed/refractory multiple myeloma.

May 02, 2020

R. Wendel Naumann, MD, gynecologic oncologist, Levine Cancer Institute, Carolinas HealthCare System/Atrium Health, discusses data with STRO-002 in patients with platinum-resistant/refractory ovarian cancer.

April 02, 2020

Jubilee Brown, MD, discusses germline and somatic testing in ovarian cancer.

March 20, 2020

Forrest Thompson, MD, discusses sequencing strategies in HER2-positive breast cancer.

February 14, 2020

The foremost choice in the treatment of patients with newly diagnosed multiple myeloma is determining whether a patient is eligible for transplant, as that choice will set the stage for all future decisions.

February 14, 2020

Saad Z. Usmani, MD, FACP, discusses the need for immediate treatment intervention in patients with relapsed/refractory multiple myeloma.

February 14, 2020

Saad Z. Usmani, MD, expands on some of the key principles to inform the treatment of patients with relapsed/refractory multiple myeloma.

February 12, 2020

Barry Paul, MD, discusses some of the newer data to emerge regarding relapsed/refractory multiple myeloma.

February 12, 2020

Barry A. Paul, MD, discusses the role of carfilzomib in the treatment of patients with relapsed/refractory multiple myeloma.

February 11, 2020

Shebli Atrash, MD, discusses investigational combinations with venetoclax (Venclexta) in relapsed/refractory multiple myeloma.

February 10, 2020

Shebli Atrash, MD, discusses some of the latest intriguing research in relapsed/refractory multiple myeloma.

February 07, 2020

Peter Voorhees, MD, provides an overview of the many developments made with CAR T-cell therapy in multiple myeloma, as well as the exciting research being done with bispecific antibodies

February 06, 2020

Saad Z. Usmani, MD, FACP, discusses treatment considerations in relapsed/refractory multiple myeloma.

February 05, 2020

Peter Voorhees, MD, discusses the role of CAR T-cell therapy in multiple myeloma.

February 04, 2020

Shebli Atrash, MD, discusses the results of the BELLINI trial examining patients with relapsed/refractory multiple myeloma.

January 17, 2020

Saad Z. Usmani, MD, FACP, discusses the results of the CANDOR trial and the impact of these data on clinical practice in multiple myeloma.

November 06, 2019

Edward S. Kim, MD, chair, Department of Solid Tumor Oncology, Levine Cancer Institute, discusses data from the phase III IMpower150 trial in advanced nonsquamous non–small cell lung cancer (NSCLC).

October 31, 2019

Saad Z. Usmani, MD, FACP, discusses the mechanisms of action of BCMA-targeted CAR T-cell therapy, bispecific monoclonal antibodies, and antibody-drug conjugates in multiple myeloma.

October 25, 2019

Edward S. Kim, MD, discusses clinical trial eligibility criteria in lung cancer.